Jia Y, Liu LL, Su JL, Meng XH, Wang WX, Tian C. Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury. World J Clin Cases 2021; 9(6): 1284-1292 [PMID: 33644195 DOI: 10.12998/wjcc.v9.i6.1284]
Corresponding Author of This Article
Cui Tian, MHSc, Attending Doctor, Department of Critical Care Medicine, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Taishan District, Tai'an 271000, Shandong Province, China. 15621589099@163.com
Research Domain of This Article
Critical Care Medicine
Article-Type of This Article
Retrospective Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Clin Cases. Feb 26, 2021; 9(6): 1284-1292 Published online Feb 26, 2021. doi: 10.12998/wjcc.v9.i6.1284
Effect of alprostadil in the treatment of intensive care unit patients with acute renal injury
Yan Jia, Li-Li Liu, Ji-Liang Su, Xiao-Hua Meng, Wei-Xin Wang, Cui Tian
Yan Jia, Li-Li Liu, Ji-Liang Su, Xiao-Hua Meng, Department of Critical Care Medicine, Shandong Taishan Hospital, Tai'an 271000, Shandong Province, China
Wei-Xin Wang, Cui Tian, Department of Critical Care Medicine, The Second Affiliated Hospital of Shandong First Medical University, Tai'an 271000, Shandong Province, China
Author contributions: Jia Y and Tian C performed the operation; Liu LL and Wang WX designed this retrospective study; Su JL and Meng XH wrote the paper; Tian C was responsible for sorting the data.
Institutional review board statement: The study was reviewed and approved by the Research Ethical Committee of Shandong Taishan Hospital Institutional Review Board, No. 2017BL-045-01.
Informed consent statement: Informed written consent was obtained from the patient for publication of this report and any accompanying images.
Conflict-of-interest statement: The authors declare that they have no conflict of interest.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Cui Tian, MHSc, Attending Doctor, Department of Critical Care Medicine, The Second Affiliated Hospital of Shandong First Medical University, No. 706 Taishan Street, Taishan District, Tai'an 271000, Shandong Province, China. 15621589099@163.com
Received: November 3, 2020 Peer-review started: November 3, 2020 First decision: November 20, 2020 Revised: December 2, 2020 Accepted: December 16, 2020 Article in press: December 16, 2020 Published online: February 26, 2021 Processing time: 95 Days and 10.4 Hours
Abstract
BACKGROUND
Acute kidney injury (AKI) is a sudden or rapid decline in the filtration function of the kidneys which is marked by increased serum creatinine or blood urea nitrogen.
AIM
To examine the value of alprostadil-assisted continuous venous-venous hemofiltration (CVVH) in the treatment of severe AKI in severely ill patients.
METHODS
This was a retrospective study and the inclusion criteria were as follows: (1) Age of patients (≥ 18 years); (2) Admission to intensive care unit due to non-renal primary disease, APACHE II score (≥ 18 points); (3) The diagnostic criteria of AKI guidelines were formulated with reference to the Global Organization for the Improvement of Prognosis in Kidney Diseases, with AKI grades of II-III; (4) All patients were treated with CVVH; and (5) Complete basic data were obtained for all patients.
RESULTS
The clinical effect of alprostadil administered in the treatment group was better than that observed in the control group (P < 0.05). The urine output of patients in the alprostadil group returned to normal time (9.1 ± 2.0 d) and was lower than that in the control group (10.6 ± 2.5 d), the difference was statistically significant (P < 0.05); adverse reactions occurred in the alprostadil group compared with the control group, but the difference was not statistically significant (P > 0.05).
CONCLUSION
Alprostadil-assisted CVVH in the treatment of severely ill patients with AKI can effectively improve the renal resistance index and partial pressure of urine oxygen, and has a positive effect on improving renal function.
Core Tip: Alprostadil-assisted continuous venous-venous hemofiltration in the treatment of severely ill patients with acute kidney injury may provide guidance and the basis for clinical practice.
